Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuL001 in healthy volunteers and idiopathic pulmonary fibrosis
NCT04540770Phase 1Completed
- Sponsor
- HuniLife Biotechnology, Inc.
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HuL001 in idiopathic pulmonary fibrosis (IPF) (4 cohorts), sponsored by HuniLife Biotechnology, Inc. Primary endpoints: Adverse Events at 84 days, Clinically Significant Abnormal Findings in Physical Examination at 84 days and 8 more. Started Aug 2021; status: completed.
02
Drugs
HuL001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04540770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540770.